⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 15, 2025

Figure S9 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer

Sofya Marchenko Niklas Goernitz Wiebke A. Zoern Maria Joosten Inga Hoffmann Jalid Sehouli Gerald Niedobitek Carsten Denkert Bruno V. Sinn Svenja Kolb José Carbonell‐Caballero Alfonso Valencia Mihnea P. Dragomir Wolfgang Schmitt David Horst Elena Ioana Braicu Christine Sers Jonathan Pohl Eliane T. Taube

View Full Paper

Ask AI

Bookmark

Share

Key Points

The CIBERSORT analysis reveals distinct cell type distributions among survivors in both cohorts.
Significant variations in immune cell types were identified, helping to understand survival differences.
Analysis utilized transcriptome data from the Charité and TCGA cohorts to enhance comparisons.
Cohort differences in immune profiles may inform future therapeutic strategies for tubo-ovarian cancer.

Implication

Analysis shows cell type distribution in advanced high-grade serous cancer cohorts, suggesting varying immune landscapes.

Abstract

Figure S9 shows CIBERSORT estimated celltypes per sample in the Charité cohort and in the TCGA cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Marchenko et al. (2025) studied this question.

synapsesocial.com/papers/68d4538731b076d99fa588f3 https://doi.org/10.1158/1078-0432.30125586

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S10 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer2025
2Figure S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer2025
3Figure S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer2025
4Table S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer2025
5Figure S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer2025